A. Sahin et al. / Tetrahedron 64 (2008) 10068–10074
10073
The mixture was stirred at ꢀ78 ꢁC for 30 min and then at room
4.11.2. Compound 16
temperature for 1 h. After quenching the mixture with water
(30 mL), the aqueous layer was extracted with diethyl ether
(3ꢂ25 mL), and the combined organic layers were washed se-
quentially with water (2ꢂ25 mL) and dried over sodium sulfate.
The solvent was removed by rotary evaporation and the crude
product was purified by short silica gel column chromatography
(CH2Cl2–hexane, 1:4, Rf¼0.90) to give 13 (860 mg, 90%) as a yellow
Yellow needle; 1H NMR (400 MHz, CDCl3)
d
9.00 (dd, J23¼4.2 Hz,
J42¼1.6 Hz, 1H, H2), 8.40 (d, J57¼2.6 Hz,1H, H7), 8.00 (dd, J43¼8.3 Hz,
J42¼1.6 Hz, 1H, H4), 7.95 (d, J32¼2.6 Hz, 1H, H5), 7.42 (dd, J34¼8.3 Hz,
J23¼4.2 Hz, 1H, H3); 13C NMR (100 MHz, CDCl3)
d
151.5, 144.1, 135.9,
nmax 3037, 2921,
135.7, 130.1,129.7, 125.9, 122.7, 119.9; IR (KBr, cmꢀ1
)
2852, 1716, 1569, 1533, 1454, 1301, 1234, 1174, 1074, 959, 937, 906,
584. Anal. Calcd for C9H5BrIN (333.95): C, 32.37; H, 1.51. Found: C,
32.40; H, 1.38.
oil. 1H NMR (400 MHz, CDCl3)
d
8.99 (d, J23¼1.5 Hz, 1H, H1,), 8.14 (d,
J32¼1.5 Hz, 1H, H3), 7.96 (d, J57¼2.1 Hz, 1H, H5,), 7.86 (d, J75¼2.1 Hz,
1H, H7), 0.45 (s, 3H), 0.39 (s, 3H); 13C NMR (400 MHz, CDCl3)
4.12. Synthesis of 4,6,8-trimethoxyquinoline (17)
d
154.0, 152.2, 146.0, 142.4, 140.0, 134.4, 132.0, 129.6, 121.7, 0.9, 0.0;
IR (neat, cmꢀ1
)
nmax 2935, 1571, 1461, 1405, 1361, 1249, 1218, 1101,
Freshly cut sodium (0.28 g, 12.3 mmol) was added under nitro-
gen gas to dry methanol (12 mL). When dissolution was completed,
the warm solution was diluted with dry dimethylformamide then
vacuum-dried cuprous iodide (0.39 g, 1.37 mmol) was added. After
dissolution, 4,6,8-tribromoquinoline (3) (0.5 g, 1.37 mmol) in dry
DMF (12 mL) was added. The reaction mixture was stirred mag-
netically under a nitrogen gas atmosphere and heated at reflux (ca.
100 ꢁC) for 48 h. The reaction’s progress was monitored by TLC and
the starting material was consumed. After cooling to room tem-
perature, H2O (50 mL) and chloroform (70 mL) were added to the
reaction mixture. The organic layers were separated, washed with
H2O (2ꢂ20 mL), and dried over sodium sulfate. The solvent was
removed and the crude product was passed through a short column
packed with silica gel (5 g). Recrystallization from a mixture of
CH2Cl2 and hexane (1:1) at room temperature yielded 4,6,8-tri-
methoxyquinoline (17) (0.18 g, 60%), colorless solid, mp 115–116 ꢁC.
993, 925, 840, 809, 754, 694, 644. Anal. Calcd for C15H22BrNSi2
(352.42): C, 51.12; H, 6.29. Found: C, 51.17; H, 6.33.
4.10. 6-Bromo-4,8-bis(methylthio)quinoline (14)
n-Butyllithium (4 mL, 1.6 M, 6.03 mmol, 2.2 equiv) was added to
a vacuum-dried flask containing tribromide 3 (1 g, 2.74 mmol) in
THF (20 mL) at ꢀ78 ꢁC. After stirring for 90 min, 1,2-dimethyldi-
sulfane [(CH3S)2, 1.6 mL, 6.85 mmol] was added to the mixture at
ꢀ78 ꢁC. The mixture was stirred at ꢀ78 ꢁC for 30 min and then at
room temperature for 1 h. After quenching with water (30 mL), the
aqueous layer was extracted with diethyl ether (3ꢂ25 mL), and the
combined organic layers were washed sequentially with water
(2ꢂ25 mL) and dried over sodium sulfate. The solvent was removed
by vacuum and the crude product was purified by short silica gel
column chromatography (2:1, hexane–EtOAc, Rf¼0.80). Re-
crystallization from CH2Cl2–Et2O (1:3, 8 mL) gave 14 (742 mg, 90%),
pale yellow needle, mp 134–135 ꢁC. 1H NMR (300 MHz, CDCl3)
1H NMR (300 MHz, CDCl3)
d
8.40 (d, J23¼2.7 Hz, 1H, H2), 7.18 (d,
J23¼2.7 Hz, 1H, H3), 6.50 (d, J57¼2.4 Hz, 1H, H7), 6.40 (d, J57¼2.4 Hz,
1H, H5), 3.97 (s, 3H), 3.89 (s, 3H), 3.87 (s, 3H); 13C NMR (75 MHz,
CDCl3)
d
159.4,156.8,154.6,140.4, 132.0,131.4, 112.4, 99.1, 96.9, 56.4,
nmax 3002, 2960, 2937, 2841, 1617, 1581,
d
8.76 (d, J23¼3.0 Hz, 1H, H2), 8.20 (d, J32¼3.0 Hz, 1H, H3), 7.60 (d,
J57¼2.0 Hz, 1H, H5), 7.79 (d, J75¼2.0 Hz, 1H, H7), 3.07 (s, 3H, SCH3),
3.05 (s, 3H, SCH3); 13C NMR (75 MHz, CDCl3)
148.2, 142.6, 141.6,
135.0, 129.6, 128.9, 124.6, 124.1, 121.0, 15.5, 14.3; IR (KBr, cmꢀ1
nmax
55.8, 55.8; IR (KBr, cmꢀ1
)
1502, 1453, 1385, 1214, 1160, 1133, 1050, 1029, 869, 827, 782. MS (EI,
70 eV) 219, 218, 190, 188, 175, 160. HRMS (EI) calcd for C12H13NO3
(Mþ): 219.0882, found: 219.0884.
d
)
3500, 1650, 1587, 1549, 1459, 1430, 1390, 1371, 1311, 1238, 1087, 989,
964, 921, 881, 860, 825, 781, 698, 605. Anal. Calcd for C11H10BrNS2
(300.24): C, 44.00; H, 3.36. Found: C, 44.03; H, 3.33.
Acknowledgements
The authors are indebted to the Gaziosmanpasa University Re-
search Fund of the Department of Chemistry (BAP, Project no.:
2003/36), State Planning Organization (DPT, Project no.:
2003K120510), and the Scientific and Technological Research
Council of Turkey (TUBITAK, Grant no.: TBAG-2027) for financial
and technical supports.
4.11. 6-Bromo-4,8-diiodoquinoline (15) and 6-bromo-8-
iodoquinoline (16)
n-Butyllithium (4 mL, 1.6 M, 6.03 mmol, 2.2 equiv) was added to
a vacuum-dried flask containing tribromide 3 (1 g, 2.74 mmol) in
THF (25 mL) at ꢀ78 ꢁC. After the mixture was stirred for 90 min,
vacuum-dried iodine (1.78 g, 7 mmol) and THF (7 mL) were added.
The mixture was stirred at ꢀ78 ꢁC for 30 min and then at room
temperature for 1 h. After quenching with saturated sodium thio-
sulfate (50 mL), the aqueous layer was extracted with diethyl ether
(3ꢂ20 mL), and the combined organic layers were washed se-
quentially with water (30 mL) and dried over sodium sulfate. After
evaporation of the solvent, formed products were purified by silica
gel columnchromatography (EtOAc–hexane,1:20). Recrystallization
from CH2Cl2–Hexane gave compounds 16 (220 mg, 46%) and 15
(80 mg, 0.87 mmol, 6%). Rf16¼0.66, Rf15¼0.32 (1:4, CH2Cl2–hexane),
mp16 194–196 ꢁC, mp15 185 ꢁC (dec).
Supplementary data
1H and 13C NMR spectra for selected compounds (15 pages) are
provided. Supplementary data associated with this article can be
References and notes
1. (a) Chauhan, P. M. S.; Srivastava, S. K. Curr. Med. Chem. 2001, 8, 1535–1542; (b)
Balasubramanian, M.; Keay, J. G. In Comprehensive Heterocyclic Chemistry II;
Katritzky, A. R., Rees, C. W., Eds.; Pergamon: New York, NY, 1996; Vol. 5, p 245;
(c) Yates, F. S. In Comprehensive Heterocyclic Chemistry; Boulton, A. J., McKillop,
A., Eds.; Pergamon: Oxford, 1984; Vol. 2, Part 2A, pp 511–524; (d) Chen, Y.-L.;
Fang, K.-C.; Sheu, J.-Y.; Hsu, S.-L.; Tzeng, C.-C. J. Med. Chem. 2001, 44, 2374–2377;
(e) Roma, G.; Braccio, M. D.; Grossi, G.; Mattioli, F.; Ghia, M. Eur. J. Med. Chem.
2000, 35, 1021–1026; (f) Morizawa, Y.; Okazoe, T.; Wang, S.-Z.; Sasaki, J.; Ebisu,
H.; Nishikawa, M.; Shinyama, H. J. Fluorine Chem. 2001, 109, 83–86; (g) Ferrarini,
P. L.; Mori, C.; Badawneh, M.; Calderone, V.; Greco, R.; Manera, C.; Martinelli, A.;
Nieri, P.; Saccomanni, G. Eur. J. Med. Chem. 2000, 35, 815–819.
4.11.1. Compound 15
Pale yellow needle; 1H NMR (400 MHz, CDCl3)
d 9.05 (d,
J23¼2.0 Hz, 1H, H2), 8.40 (d, J32¼2.0 Hz, 1H, H2), 8.35 (d, J57¼2.7 Hz,
1H, H5), 7.80 (d, J75¼2.7 Hz, 1H, H7); 13C NMR
d (100 MHz, CDCl3)
157.2, 144.6, 143.4, 143.2, 130.6, 129.8, 121.6, 104.6, 92.3; IR (KBr,
d
cmꢀ1
)
nmax 3019, 2401, 1639, 1423, 1214, 1047, 929, 877, 755, 669.
2. Antibiotics II, Biosynthesis; Gottlieb, D., Shaw, P. D., Eds.; Springer: New York, NY,
1967; Vol. 2, p 105.
3. Noverty, J.; Collins, C. H.; Starts, F. W. J. Pharm. Sci. 1974, 63, 1264–1267.
Anal. Calcd for C9H4BrI2N (459.85): C, 23.51; H, 0.88. Found: C,
23.64; H, 0.94.